Research programme: mineralocorticoid receptor modulators - Ligand Pharmaceuticals
Latest Information Update: 18 Sep 2006
At a glance
- Originator Ligand Pharmaceuticals
- Class
- Mechanism of Action Mineralocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Heart failure in USA (PO)
- 18 Sep 2006 Discontinued - Preclinical for Hypertension in USA (PO)
- 11 Jul 2003 This programme is still in active development for congestive heart failure and hypertension